Table 3. The miRNA exosomes in screening and diagnostic.
| Cancer type | Results | Observation | Role | Reference |
|---|---|---|---|---|
| MBL and CLL | miR-155 (↑) | Exosomal and whole blood of 224 samples from 2 independent training and validation cohorts | Diagnostic, patient stratification | 66 |
| Prostate cancer (PCa) | miR-141(↑), miR-181a-2*(↓), miR-301a(↑), miR-326(↑), miR-331-3p(↑), miR-375(↑), miR-432(↑), miR-574-3p(↑), miR-625*(↑), miR-210(↑) | Plasma and serum microvesicles PCa versus healthy controls, 106 patients for screening; validation on 119 patients for metastatic versus localized PCa (only for mir-141 miR-375) | Diagnostic, prognostic | 67, 73 |
| Ovarian cancer | miR-21(↑), miR-141(↑), miR-200a(↑), miR-200c(↑), miR-203(↑), miR-205(↑) and miR-214(↑) | Different stages of ovarian cancer (50 cases) versus benign ovarian adenoma (n=10) | Diagnostic | 92 |
| Lung cancer | miR-17-3p(↑), miR-21(↑), miR-106a(↑), miR-146(↑), miR-155(↑), miR-191(↑), miR-192(↑), miR-203(↑), miR-205(↑), miR-210(↑), miR-212(↑), miR-214(↑) | Exosomal and free miRNA in plasma for lung cancer versus control group | Screening and diagnostic | 94 |
| Melanoma | miR-31(↑), miR-185(↑), and miR-34b(↑) | Tumor cell-derived exosomes and normal melanocyte-derived exosomes | Biomarkers | 63 |
| Esophageal squamous cell carcinoma (ESCC) | miR-1246(↑) | Serum and exosomes | Diagnostic, prognostic | 95 |
The symbol ‘↑' indicates overexpressed and ‘↓' indicates downregulated